Nanoparticles |
Omeprazole |
In vitro In vivo antiulcer activity (rats) |
-
Enteric-coated nanocapsules,
-
Functional polymers: HPMCP, PVAP,
-
Obtained by emulsification method
|
In vitro In vivo antiulcer activity (rats) |
-
Enteric-coated nanoparticles,
-
Functional polymers: Eudragit L 100–55, chitosan,
-
Obtained by complex coacervation method
|
Pantoprazole |
In vitro |
-
pH-sensitive polymeric nanoparticles,
-
Functional polymers: Eudragit S 100, HPMCP (HP–55),
-
Obtained by nanoprecipitation method
|
In vitro |
-
Sustained-release solid lipid nanoparticles (SLNs),
-
Functional polymers: ethylcellulose, chitosan, HPMC K100, PVA,
-
Obtained by nanoprecipitation method
|
Pantoprazole + Aceclofenac |
In vitro In vivo (rats) |
-
Sustained-release nanofibers,
-
Functional polymers: zein, Eudragit S 100,
-
Obtained by single nozzle electrospinning
|
Lansoprazole |
In vitro |
-
Sustained-release nanoparticles,
-
Functional polymers: Eudragit RS 100,
-
Obtained by oil-in-water emulsion-solvent evaporation method
|
In vitro |
-
Controlled-release nanosponges,
-
Functional polymers: ethylcellulose, PVA,
-
Obtained by emulsion solvent diffusion method
|
In vitro |
|
In vitro |
-
Nanosuspensions composed of β-cyclodextrin-API complexes or β -cyclodextrin-API nanosponges,
-
Obtained by physical method or polymer condensation method respectively
|
Lansoprazole + curcumin |
In vitro |
-
Bioactive solid self-nanoemulsifying drug delivery systems (Bio-SSNEDDS),
-
Functional excipients: black seed oil, Zanthoxylum rhetsa oil,
-
Obtained by emulsification method
|
Esomeprazole |
In vitro Ex vivo permeability study In vivo PK and PD studies (rats) |
-
Proniosomes,
-
Functional excipients: maltodextrin (carrier), cholesterol,
-
Obtained by slurry method
|
Microparticles |
Omeprazole |
In vitro In vivo PK study (rabbits) |
-
β-cyclodextrin-API complexes encapsulated with antacids in gelatine capsule,
-
Functional excipients: NaHCO3, Na2CO3, MgO, Mg(OH)2,
-
Obtained by saturated aqueous solution method
|
In vitro |
-
Microcapsules composed of Lactobacillus acidophilus surface layer protein,
-
Functional excipients: ATCC 4356 S-layer protein
|
In vitro |
-
Complexes of latex particles with API,
-
Functional polymers: Aquateric (cellulose acetophthalate latex),
-
Obtained by adsorption method
|
In vitro |
-
Immediate-release microparticles,
-
Functional polymers: Kollicoat IR, hydroxypropyl-β-cyclodextrin,
-
Obtained by spray-drying or freeze-drying
|
In vitro |
-
Gastro-resistant microparticles,
-
Functional polymers: Eudragit S 100, hydroxypropyl-β-cyclodextrin (carrier),
-
Obtained by spray-drying or emulsification method
|
Omeprazole + piperine |
In vivo PK and bioavailability studies (rabbits) |
-
Gastroretentive microspheres,
-
Functional polymers: ethylcellulose, HPMC
-
Obtained by emulsification-solvent evaporation method
|
Omeprazole + clarithromycin |
In vitro |
-
Sustained-release mucoadhesive microspheres,
-
Functional polymers: HPMC K4M/K100M, Carbopol 971p
-
Obtained by non-aqueous emulsification-solvent evaporation method
|
Pantoprazole |
In vitro |
-
Gastro-resistant microparticles with improved photostability,
-
Functional polymers: Eudragit S 100,
-
Obtained by solvent evaporation method
|
In vitro |
-
Microparticles with improved photostability,
-
Functional polymers: Eudragit S 100, poly(e-caprolactone), HPMC,
-
Obtained by emulsification- solvent evaporation method or spray-drying
|
In vitro |
-
Gastro-resistant microparticles,
-
Functional polymers: Eudragit S 100, HPMCP (HP–55),
-
Obtained by emulsion-solvent evaporation method
|
In vitro |
-
Sustained-release floating microspheres,
-
Functional polymers: Eudragit S 100, HPMC K100M,
-
Obtained by non-aqueous solvent evaporation method
|
In vitro |
-
Double-walled sustained-release microspheres,
-
Functional polymers: HPMC, sodium alginate (1st layer), Eudragit RS 100 (2nd layer),
-
Obtained by emulsification- solvent evaporation method
|
In vitro |
-
Sustained-release microsponges,
-
Functional polymers: Eudragit RS 100,
-
Obtained by quasi-emulsion solvent diffusion method
|
In vitro In vivo antiulcer activity (rats) |
-
Enteric-coated, controlled-release microparticles,
-
Functional polymers: Eudragit S 100, poly(ε-caprolactone),
-
Obtained by solvent evaporation method
|
In vitro In vivo antiulcer activity (rats) |
-
Gastro-resistant microparticles,
-
Functional polymers: Eudragit S 100,
-
Obtained by O/O emulsification- solvent evaporation method
|
In vitro In vivo antiulcer activity (rats) |
-
Floating microballons,
-
Functional polymers: Eudragit L 100, Eudragit RS 100,
-
Obtained by emulsion solvent diffusion method
|
In vitro In vivo antiulcer activity (rats) |
-
Gastro-resistant, controlled-release microparticles,
-
Functional polymers: Eudragit S 100, Methocel F4M
-
Obtained by spray-drying
|
In vitro |
-
Gastro-resistant microparticles (agglomerates),
-
Functional polymers: Eudragit S 100, Methocel F4M,
-
Obtained by spray-drying
|
In vitro |
-
Gastro-resistant microparticles,
-
Functional polymers: Eudragit S 100,
-
Obtained by spray-drying (performed in various conditions)
|
In vivo bioavailability study (dogs) |
-
Gastro-resistant microparticles (soft agglomerates),
-
Functional polymers: Eudragit S 100,
-
Obtained by spray-drying
|
In vitro In vivo antiulcer activity (rats) |
-
Gastro-resistant microparticles,
-
Functional polymers: Eudragit S 100, Eudragit RS 100,
-
Obtained by spray-drying
|
In vitro |
-
Gastro-resistant microspheres,
-
Functional polymers: ethylcellulose, HPC (1st layer), Eudragit L-100, sodium alginate (2nd layer),
-
Obtained by emulsification-solvent evaporation method
|
Lansoprazole |
In vitro In vivo PK and antiulcer activity studies (rats) |
-
Enteric-coated, sustained-release microparticles,
-
Functional polymers: Eudragit RS 100, Eudragit S 100, HPMCP (HP–55),
-
Obtained by solvent evaporation method, coated in fluidized bed
|
In vitro |
-
Enteric-coated microspheres,
-
Functional polymers: cellulose acetate phthalate (CAP),
-
Obtained by solvent evaporation method
|
In vitro |
-
Sustained-release, floating microspheres,
-
Functional polymers: ethylcellulose, HPMC,
-
Obtained by solvent evaporation method
|
In vitro |
-
Enteric-coated micropellets,
-
Functional polymers: HPMC E5 (sublayer), Acrycoat L-30D
-
Obtained by fluid bed coating
|
In vitro |
-
Sustained-release, floating micropellets,
-
Functional polymers: HPMC, MC, chitosan,
-
Obtained by emulsion- solvent diffusion method
|
In vitro |
-
Gastro-resistant microparticles,
-
Functional polymers: Eudragit S 100, Eudragit L 100, Eudragit L100-55,
-
Obtained by spray-drying
|
In vitro |
-
Enteric-coated, sustained-release microspheres,
-
Functional polymers: Eudragit RS 100 (1st layer), HPMCP (HP-55) (2nd layer),
-
Obtained by solvent evaporation method and spray-drying
|
In vitro |
-
Cyclodextrin metal-organic frameworks (CD-MOFs) microparticles with improved thermostability,
-
Functional excipients: γ-CDs, KOH, cetyltrimethyl ammonium bromide (CTAB) (stabilizer)
|
Rabeprazole |
In vitro In vivo antiulcer activity (rats) |
-
Gastro-resistant, sustained-release mucoadhesive microspheres,
-
Functional polymers: ethylcellulose, Eudragit L 100, HPMC, CMC sodium, HEC, HPC,
-
Obtained by solvent evaporation method and dip coating technique
|
In vitro |
-
Sustained-release floating microspheres,
-
Functional polymers: ethylcellulose, HPMC K15M,
-
Obtained by emulsification- solvent evaporation method
|
In vitro In vivo floating study (rabbits) |
-
Controlled-release floating microbeads,
-
Functional polymers: sodium alginate, HPMC, BaCl2/ CaCl2 (crosslinking agents),
-
Obtained by ionotropic gelation method
|
Rabeprazole + amoxicillin |
In vitro In vivo antiulcer activity and radiographic study (rats) |
-
Sustained-release microballoons,
-
Functional polymers: Eudragit S 100, HPMC,
-
Obtained by emulsion solvent diffusion method
|
Esomeprazole |
In vitro |
-
Sustained-release floating microspheres,
-
Functional polymers: HPMC, MC, chitosan,
-
Obtained by solvent evaporation method
|
Minitablets |
Omeprazole |
In vitro |
-
Enteric-coated minitablets,
-
Functional coating: HPMC (sublayer), Eudragit L 30D-55,
-
Obtained by direct compression, coated in fluidized bed
|
Pantoprazole |
In vitro |
-
Enteric-coated minitablets,
-
Functional coating: Eudragit L 30D-55, Acryl-Eze II
-
Obtained by direct compression, coated in fluidized bed
|
Pellets |
Omeprazole |
In vitro In vivo PK and gastro-resistance studies (dogs/rats) |
-
Enteric-coated pellets,
-
Functional polymers: HPMC (sublayer), Eudragit L 30D-55,
-
Core pellets coated in fluidized bed
|
In vitro In vivo PK and bioequivalence studies (rabbits) |
-
Delayed-release pellets,
-
Functional excipients: MMC, lactose, PVP K30,
-
Obtained by sieving-spheronization and extrusion-spheronization methods
|
In vitro In silico (ANN, modelling tablet properties) |
-
Enteric-coated pellets,
-
Functional polymers: HPMC (sublayer), Eudragit L 30D-55,
-
Core pellets coated in fluidized bed
|
In vitro |
-
Gastro-resistant, alginate beads,
-
Functional polymers: sodium alginate, SBA-15 mesoporous matrix
|
In vitro |
-
Multiparticulate pulsatile drug delivery system,
-
Functional excipients: HPMC, ethylcellulose, Eudragit RS 30D, Eudragit RL 30D, NaCl (osmogent),
-
Obtained by film casting/extrusion-spheronization method or fluid bed coating
|
Pantoprazole |
In vitro |
-
Enteric-coated pellets,
-
Functional polymers: Eudragit L100-55 (organic/aqueous dispersion), Eudragit L 30D-55,
-
Obtained by film casting and extrusion-spheronization method
|
Lansoprazole |
In vitro |
-
Gastro-resistant multilayer pellets,
-
Functional excipients: Na2CO3 (alkaline layer), HPMC (sublayer), Eudragit L 30D-55 (outerlayer),
-
Core pellets coated in fluidized bed
|
In vitro |
|
In vitro |
-
Gastro-resistant pellets,
-
Functional excipients: carboxymethyl tamarind kernel powder (CMTKP), croscarmellose sodium, MCC,
-
Obtained by extrusion-spheronization method
|
In vitro In vivo PK study (dogs) |
-
Gastro-resistant pellets,
-
Functional polymers: HPMC, aqueous enteric coating,
-
Obtained by fluid-bed granulation, coated in fluidized bed
|
In vitro |
|
In vitro In vivo bioavailability study (dogs) |
|
Rabeprazole |
In vitro |
|
In vitro |
|
In vitro |
|
Esomeprazole |
In vitro In vivo PK study (rats) IVIVC |
-
Sustained-release, enteric-coated pellets,
-
Functional coating: HPC-EF/HPMC-E5 (sublayer), Eudragit RS 30D/RL 30D (1st layer), Eudragit L 30D-55 (2nd layer),
-
Coated in fluidized bed
|
In vitro In silico (ANN, coating process) |
|
Tablets |
Omeprazole |
In vitro |
|
In vitro |
|
In vitro |
-
Lyophilized orally disintegrating tablets containing enteric-coated pellets,
-
Fast disintegration of tablets combined with gastric resistance of pellets and their immediate release in phosphate buffer
|
Omeprazole + domperidone |
In vitro |
-
Directly compressed fast disintegrating tablets,
-
Combination of two APIs in one tablet,
-
No stability considerations
|
Pantoprazole |
In vitro |
-
API complex with rosin used to protect it from low pH,
-
Complexes directly tabletted with different superdisintegrants: sodium starch glycolate, crospovidone, croscarmellose sodium
|
In vitro In vivo antiulcer activity (rats) |
-
Sustained-release, enteric-coated tablets,
-
Slow release was achieved by forming matrix using HPMC, cassava starch or PVP,
-
Enteric coating: cellulose acetate phthalate (CAP) or Eudragit L 100,
-
No degradation of API in acid phase detected; prolonged release for 10 h in a buffer stage (first-order kinetic)
|
In vitro |
-
Pulsatile drug delivery system,
-
Immediate-release tablets press-coated with ethylcellulose and HPMC mixed in different ratios,
-
Drug release lag time from 1.5 up to 3 h was achieved
|
In vitro |
-
Multiunit particulate system tablets (MUPS),
-
Pantoprazole pellets coated with Eudragit L and with cushion layer,
-
Fast-disintegrating tablets were achieved with a drug release in the acid phase lower than 6%, followed by immediate release in the buffer
|
In vitro |
-
Orodispersible tablets with crospovidone or sodium starch glycolate were directly compressed with API,
-
Stability issues were not considered
|
Lansoprazole |
In vitro |
-
Delayed-release tablets,
-
Immediate-release tablets press-coated with ethylcellulose and two different grades of HPMC,
-
Drug release lag time from 2 up to 4 h was achieved
|
In vitro |
-
Hot-melt extrusion used to combine lansoprazole with PVP, Lutrol F68 and magnesium oxide,
-
Extrudates compressed to core tablets, which were coated with Eudragit L100-55,
-
No drug release during 1 h acid stage, followed by immediate release to a buffer
|
In vitro In vivo absorption studies (dogs), disintegration time in the mouth (human) |
-
Orodispersible tablets containing enteric coated microgranules,
-
Enteric coating: Eudragit L30D-55 and Eudragit NE30D,
-
Bioequivalence was demonstrated with a manufactured drug
|
In vitro |
-
Fast-dissolving tablets,
-
For solubility improvement solid dispersions of lansoprazole with PEG 4000/6000 or drug-β-cyclodextrin complexes were formed,
-
Tablets prepared by direct compression with superdisintegrants,
-
Degradation of API in acid was not considered in the study
|
In vivo (human) Clinical trials |
|
In vivo (human) |
-
In the study the effect of water intake on lansoprazole absorption from orodispersible tablets was evaluated,
-
No significant difference between administration with or without water was observed
|
In vivo bioequivalence studies (human) |
-
Bioequivalence studies on orodispersible tablets and capsules containing lansoprazole,
-
No significant differences between Cmax and AUC values of tested formulations were observed
|
In vitro In vivo (human) |
-
Comparison of branded and five generic orodispersible tablets containing lansoprazole,
-
Formulation quality (stability in saliva, dissolution in acidic and intestinal media) and ingestibility were tested
|
In vitro |
|
Rabeprazole |
In vitro In vivo PK studies (beagle dogs) |
-
Immediate-release formulation containing rabeprazole core tablet dry-coated with sodium bicarbonate,
-
Faster onset of action in comparison to reference tablets
|
In vitro |
|
In vitro |
-
Enteric-coated tablets,
-
Core tablets prepared by direct compression or after wet granulation,
-
Coating with HPMCP (Instacoat EN-HPMCP)
|
In vitro |
|
In vitro |
-
Sustained-release tablets,
-
Matrix tablet were prepared after wet granulation of API with HPMC, Carbopol or sodium carboxymethyl cellulose,
-
Degradation of API in acid was not considered in the study
|
In vitro |
-
Orodispersible tablets,
-
Different superdisintegrants evaluated: crospovidone, croscarmellose sodium, pregelatinized starch, L-HPC, treated agar ,
-
Degradation of API in acid was not considered in the study
|
Esomeprazole |
In vitro |
|
In vitro |
|
In vitro Ex vivo permeation studies (porcine mucosa) In vivo pharmacokinetics studies (rats) |
-
Immediate-release tablets containing magnesium oxide or sodium bicarbonate as an acid protective ingredients,
-
Minitablets with esomeprazole and sodium bicarbonate coated with Eudragit L100-55,
-
Addition of bicarbonate promoted esomeprazole permeation and its immediate absorption
|
In vitro |
-
Colon-specific drug delivery system,
-
Core tablets were press-coated with a mixture of HPMCP and ethyl cellulose,
-
Drug release sustained up to 6 h in buffer stage
|
In vitro |
-
Multiunit particulate system (MUPS) tablets,
-
Enteric-coated pellets compressed with different excipients (lactose, dibasic calcium phosphate) to form of tablet,
-
High resistance to acid degradation, followed by immediate API release in buffer
|
Dexlansoprazole |
In vitro |
-
Extended-release tablets,
-
Directly compressed tablets containing HPMC and HPMCP were coated with shellac,
-
Drug release extended up to 12 h,
|
Tenatoprazole |
In vitro |
-
Enteric-coated tablets,
-
Directly compressed tablets were coated with HPMCP, Eudragit L 30D-55, or HPMCAS,
-
Drug release extended up to 12 h
|
In vitro |
-
Extended-release matrix tablets,
-
Direct compression of API with polymers such as Carbopol, Methocel or Eudragit, and sodium bicarbonate as a pH controlling agent,
-
Drug release extended up to 12 h
|
Ilaprazole |
In vitro |
-
Enteric-coated tablets,
-
Compression of the core tablets after wet granulation,
-
Coating with Eudragit L 100 or HPMCP,
-
Efficient gastric protection followed by immediate release in buffer stage was achieved
|
|
|
In vitro |
-
Extended-release tablets,
-
Direct compression of the core tablets containing different superdisintegrants,
-
Coating with HPMCP and Eudragit L 100,
-
Efficient gastric protection followed by drug release extended up to 12 h was achieved
|
Fixed-dose combination products |
Esomeprazole + naproxen |
In vitro |
-
Hot-melt co-extrusion was used to produce cylindrical systems,
-
The core of the cylinder contained naproxen with enteric polymers like Eudragit, HPMC-AS-LF, HPMCP or Eudragit L100-55,
-
The outer layer of the cylinder contained esomeprazole with immediate release polymers such as Kollidon, Klucel, Methocel or PEO,
-
Degradation of esomeprazole in acidic medium was not considered in the study
|
Bilayer tablets |
Lansoprazole + amoxycillin |
In vitro |
-
Bilayer tablets,
-
Immediate-release layer containing lansoprazole, sodium starch glycolate and MCC,
-
Sustained release layer with amoxicillin, HPMC and EC,
-
Degradation of lansoprazole in acidic medium was not considered in the study
|
Esomeprazole + aceclofenac |
In vitro |
-
Bilayer floating tablets,
-
Immediate-release layer contained esomeprazole, sodium bicarbonate, citric acid, and sodium starch glycolate,
-
Sustained release layer contained HPMC in different grades and xanthan gum,
-
Degradation of esomeprazole in acidic medium was not considered in the study
|
Esomeprazole + clarithromycin |
In vitro |
-
Controlled-release floating effervescent bilayer tablets,
-
Combination of Eudragit RS 100 and Carbopol was used to control drug release in both layers,
-
Sustained release for up to 24 h was achieved,
-
Degradation of esomeprazole in acidic medium was not considered in the study
|
Esomeprazole + levosulpiride |
In vitro |
-
Bilayer tablets,
-
Immediate-release layer containing esomeprazole with superdisintegrants such as croscarmellose sodium, crospovidone or sodium starch glycolate,
-
Sustained release floating layer contained levosulpiride, HPMC, sodium bicarbonate and citric acid,
-
Immediate release of esomeprazole and 12 h release of levosulpiride were achieved,
-
Degradation of esomeprazole in acidic medium was not considered in the study
|
Floating tablets |
Pantoprazole |
In vitro |
-
Floating effervescent tablets,
-
Tablets contained pectin, HPMC, sodium bicarbonate, calcium carbonate and citric acid granulated with isopropyl alcohol prior to compression,
-
Pantoprazole release was extended up to 8 h,
-
Degradation of pantoprazole in acidic medium was not considered in the study
|
In vitro |
-
Sustained release floating tablets,
-
Direct compression used to prepare tablets containing API, HPMC or sodium alginate with MCC and sodium bicarbonate,
-
Pantoprazole release was extended up to 8 h,
-
Degradation of pantoprazole in acidic medium was not considered in the study
|
Lansoprazole |
In vitro |
-
Sustained release floating tablets,
-
Direct compression used to prepare tablets containing API, HPMC and sodium bicarbonate,
-
Lansoprazole release extended to 10 h,
-
Degradation of API in acidic medium was not considered in the study
|
In vitro |
-
Sustained release effervescent floating tablets,
-
Direct compression used to prepare tablets containing API, xanthan gum, gellan gum, Carbopol or chitosan, citric acid and sodium bicarbonate,
-
Lansoprazole release extended to 12 h,
-
Degradation of API in acidic medium was not considered in the study
|
Rabeprazole |
In vitro In vivo pharmacokinetic and antiulcer activity studies (rats) |
-
Immediate-release floating tablets,
-
Wet granulation with ethanolic solution of HPMC was used to prepare granules containing API, pectin, mannitol, PEG 400, sodium bicarbonate, calcium carbonate and citric acid,
-
Floating tablets neutralize gastric acid to protect API from degradation,
-
Faster onset of action and better antiulcer activity was achieved as compared to the commercial rabeprazole delayed-release capsules
|
Hydrogel formulations |
Pantoprazole |
In vitro |
-
Colon-specific controlled release hydrogel,
-
Gum tragacanth and acrylic acid based hydrogel was prepared by graft copolymerization,
-
pH-sensitive drug release rate was achieved,
-
Pantoprazole released extended up to 30 h
|
In vitro |
-
Superporous hydrogel with pantoprazole,
-
Methacrylic acid and acrylamide were polymerized in the presence of N,N-methylene-bis-acrylamide as crosslinking agent,
-
High acid resistance and extended pantoprazole release up to 6 h was achieved
|
In vitro In vivo studies on hydrogel gastro-retention (mice) |
-
In situ gelling formulation,
-
Gellan gum, sodium alginate and HPMC were used as a gelling agents,
-
Pantoprazole release extended to 12 h,
-
Degradation of API in acidic medium was not considered in the study
|
Rabeprazole |
In vitro |
-
Hydrogel beads intended for the colon delivery of rabeprazole,
-
Hydrogel beads were prepared by ionotropic gelation of sodium alginate with calcium chloride,
-
Eudragit S100 used for enteric-coating of beads,
-
Gastric protection of rabeprazole was achieved followed by 8 h drug release
|
Mucoadhesive tablets |
Omeprazole |
In vitro |
-
Mucoadhesive tablets with pellets inside,
-
Tablets were coated with mucoadhesive polymer: HPMC K4M, sodium carboxymethylcellulose, ethyl cellulose or Carbopol 934P, and then with Eudragit L100 to achieve final enteric coating
|
In vitro In vivo studies on absorption from the oral cavity and tablets adhesion to the oral mucosa (human) |
-
Buccal adhesive tablets,
-
Sodium alginate and HPMC were used as a mucoadhesive polymers,
-
Magnesium oxide, potassium phosphate monobasic, sodium phosphate monobasic and dibasic were used as a pH-stabilizers,
-
Stability of API in human saliva for 4 h was achieved
|
In vitro In vivo pharmacokinetic studies (hamsters) |
-
Omeprazole buccal adhesive tablets,
-
API was directly compressed with sodium alginate, HPMC, magnesium oxide, and croscarmellose sodium,
-
Sustained drug release was confirmed in pharmacokinetic studies; constant omeprazole level in blood was maintained for 6 h
|
In vitro In vivo pharmacokinetic studies (hamster), mucoadhesive force measurement (human) |
-
Buccal adhesive tablets with omeprazole,
-
API was directly compressed with sodium alginate, HPMC, magnesium oxide, and croscarmellose sodium,
-
Sustained drug release was confirmed in pharmacokinetic studies; constant omeprazole level in blood was maintained for 6 h
|
In vitro |
-
Pediatric buccal film,
-
Casting method was used to prepare films with omeprazole, HPMC, MC, sodium alginate, carrageenan, metolose, PEG 400 and L-arginine
|
Pantoprazole |
In vitro |
-
Sustained release mucoadhesive gastroretentive system,
-
Tablets containing API, MCC, PVP, and HPMC, Carbopol, or guar gum were prepared with direct compression,
-
Extended release of pantoprazole was achieved for 10 h,
-
Degradation of API was not analyzed in the study
|
Oral liquid suspensions |
Omeprazole |
In vitro |
-
Study on physicochemical and microbiological stability,
-
Suspension composed of crushed omeprazole pellets or pure omeprazole in a complex vehicle
|
In vitro |
-
Enteric-coated particles for suspension in syrup (extemporaneously),
-
Functional polymes: Eudragit E 100, Eudragit L100-55,
-
Particles obtained by fluid bed coating
|
In vitro In vivo preliminary toxicity and antiulcer activity studies (mice) |
-
Enteric-coated nanoparticles for oral liquid suspension,
-
Functional polymes: Eudragit RS 100 (1st layer), Eudragit L100-55 (2nd layer),
-
Obtained by interfacial deposition of the preformed polymers method
|
Transdermal delivery |
Omeprazole |
In vivo PK study (human) |
-
Study on omeprazole transdermal absorption,
-
Transdermal gel formulation: pleuronic lecithin organogel (PLO) containing omeprazole (50 mg/mL)
|
Lansoprazole |
Ex vivo penetration study (pigs) In vivo PK study (rats) |
-
Nanostructured lipid carriers (NLCs) for hydrogel formulations,
-
Functional excipients: glyceryl monostearate, stearylamine, SDS, isopropyl myristate, menthol
|
Rabeprazole |
Ex vivo penetration study (snake) |
-
Transdermal patches,
-
Film forming polymers: HPC-EF, PVP K30, PVP K90,
-
Obtained by solvent casting method
|
Suppositories |
Omeprazole |
In vitro |
|
Clinical trial (efficacy, PK) |
|
Intravenous formulations |
Omeprazole |
In vitro |
-
Powder for solution for infusion with cyclodextrins as stability enhancers,
-
Obtained by lyophilization
|
In vitro |
-
Nanosuspension,
-
Suspension components: 8.4% sodium bicarbonate solution, Poloxamer 188 (1%),
-
Obtained by DissoCubes® technology
|